S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in

NantKwest Stock Forecast, Price & News

+0.25 (+1.47 %)
(As of 01/22/2021 12:00 AM ET)
Today's Range
Now: $17.25
50-Day Range
MA: $13.79
52-Week Range
Now: $17.25
Volume801,426 shs
Average Volume1.87 million shs
Market Capitalization$1.87 billion
P/E RatioN/A
Dividend YieldN/A
NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.
NantKwest logo


Overall MarketRank

1.13 out of 5 stars

Medical Sector

883rd out of 1,925 stocks

Biological Products, Except Diagnostic Industry

114th out of 177 stocks

Analyst Opinion: 1.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic



Sales & Book Value

Annual Sales$40,000.00
Price / Sales46,830.73
Book Value$1.23 per share


Net Income$-65,790,000.00
Net Margins-76,658.58%


Market Cap$1.87 billion
Next Earnings Date3/24/2021 (Estimated)
+0.25 (+1.47 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NK News and Ratings via Email

Sign-up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

NantKwest (NASDAQ:NK) Frequently Asked Questions

How has NantKwest's stock been impacted by COVID-19 (Coronavirus)?

NantKwest's stock was trading at $3.52 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NK shares have increased by 390.1% and is now trading at $17.25.
View which stocks have been most impacted by COVID-19

Is NantKwest a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NantKwest in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NantKwest stock.
View analyst ratings for NantKwest
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than NantKwest?

Wall Street analysts have given NantKwest a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NantKwest wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as NantKwest's CEO?

1,448 employees have rated NantKwest CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among NantKwest's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is NantKwest's next earnings date?

NantKwest is scheduled to release its next quarterly earnings announcement on Wednesday, March 24th 2021.
View our earnings forecast for NantKwest

How were NantKwest's earnings last quarter?

NantKwest, Inc. (NASDAQ:NK) posted its earnings results on Monday, May, 11th. The biotechnology company reported ($0.19) EPS for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.02. The biotechnology company earned $0.02 million during the quarter. NantKwest had a negative return on equity of 56.06% and a negative net margin of 76,658.58%.
View NantKwest's earnings history

What price target have analysts set for NK?

1 brokers have issued 12-month price targets for NantKwest's shares. Their forecasts range from $18.00 to $18.00. On average, they anticipate NantKwest's share price to reach $18.00 in the next year. This suggests a possible upside of 4.3% from the stock's current price.
View analysts' price targets for NantKwest
or view Wall Street analyst' top-rated stocks.

Who are some of NantKwest's key competitors?

What other stocks do shareholders of NantKwest own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NantKwest investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Trevena (TRVN) and ADMA Biologics (ADMA).

Who are NantKwest's key executives?

NantKwest's management team includes the following people:
  • Dr. Barry J. Simon, Pres, Chief Admin. Officer & Exec. Director (Age 55, Pay $454.44k)
  • Ms. Sonja Nelson, Chief Financial Officer (Age 47, Pay $442.69k)
  • Mr. Richard Gerald Adcock, Chief Exec. Officer (Age 52)
  • Mr. Steven Yang J.D., VP, Gen. Counsel & Corp. Sec.
  • Dr. Jerel A. Banks Ph.D., M.D., Sr. VP Mergers and Acquisitions (Age 45)
  • Mr. Leonard S. Sender, Sr. VP of Medical Affairs - Pediatric, Adolescent & Young Adult Oncology
  • Dr. Hans Georg Klingemann, VP of R&D (Age 70)

When did NantKwest IPO?

(NK) raised $150 million in an initial public offering (IPO) on Tuesday, July 28th 2015. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray acted as the underwriters for the IPO and MLV & Co. was co-manager.

What is NantKwest's stock symbol?

NantKwest trades on the NASDAQ under the ticker symbol "NK."

Who are NantKwest's major shareholders?

NantKwest's stock is owned by a variety of retail and institutional investors. Top institutional investors include Clearwater Capital Advisors LLC (0.03%). Company insiders that own NantKwest stock include Barry J Simon, Frederick W Driscoll, John C Thomas, Patrick Soon-Shiong and Sonja Nelson.
View institutional ownership trends for NantKwest

Which institutional investors are buying NantKwest stock?

NK stock was bought by a variety of institutional investors in the last quarter, including Clearwater Capital Advisors LLC.
View insider buying and selling activity for NantKwest
or or view top insider-buying stocks.

How do I buy shares of NantKwest?

Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NantKwest's stock price today?

One share of NK stock can currently be purchased for approximately $17.25.

How big of a company is NantKwest?

NantKwest has a market capitalization of $1.87 billion and generates $40,000.00 in revenue each year. The biotechnology company earns $-65,790,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. NantKwest employs 160 workers across the globe.

What is NantKwest's official website?

The official website for NantKwest is www.nantkwest.com.

How can I contact NantKwest?

NantKwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]

This page was last updated on 1/23/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.